MediWound Join Hands with 3M Health Care on EscharEx Phase III Study

MediWound Ltd., a fully integrated bio pharmaceutical firm focused on next-generation enzymatic treatments for tissue repair, has established a partnership with 3M Health Care.3M Health Care will deliver its market-leading two-layer compression systems Coban 2 and Coban 2 Lite for use during the EscharEx phase III study's debridement and wound healing phases.

"One of our primary goals in our pursuit of excellence is to ensure consistency across subjects while providing optimal care throughout the study." "3M Health Care's Coban compression systems are global market leaders , and we're pleased to designate them as the standard for our Phase 3 study," said Ofer Gonen, CEO of MediWound. "Because compression therapy is critical in the treatment of venous leg ulcers (VLUs), we must use high-quality products." We're convinced we're doing precisely that with 3M Health Care's two-layer compression solutions."

EscharEx is being tested for efficacy and safety in the debridement of chronic wounds, with VLUs being the primary indication. 3M's two-layer compression systems will be used as standard of care in all study arms during the debridement and wound healing phases of the study, until the wounds heal completely, as per pharmabiz. "We are excited to partner with MediWound on this pivotal Phase III study. Establishing Coban 2 and Coban 2 Lite as the benchmark in compression therapy underscores the brand's leadership and reinforces its position as the top choice for VLU patients," said Rob Steel, Global Portfolio Director at 3M Health Care. "We anticipate leveraging the comprehensive data from the study to convey to clinicians and payors the clinical and economic advantages of our compression systems."